Psoriatic arthritis is a heterogeneous chronic inflammatory disease with a wide clinical spectrum and variable course. While targeted therapeutic options are broadening, comorbidity management continues to remain a challenge. The search for outcome measures specific to PsA continues as does the push for a treat to target approach? The challenges for the clinician and researcher remain significant and will be explored.